Prospective Clinical Data

Prospective Case Studies of Champions TumorGraft®-Guided Therapy*

  • 14 patients with advanced cancer whose treatments were selected based on activity against a personalized Champions TumorGraft PDX model developed from the patient’s own cancer
  • Data showed a high correlation between drug activity in the model and clinical outcome, both in terms of resistance and sensitivity
  • Excellent performance irrespective of the line of treatment and tumor type in the therapy in nine different tumor types, including lung, gastroesophageal, colorectal, pancreatic and others
  • Treatments selected for each individual patient would have not been the first choice for a conventional second- or third-line treatment
  • Objective response rate was 88 percent for treatments deemed effective by the model and tested in the patients
  • In 11 out of 13 patients, we found a recommended drug or drug combination treatment
  • Of these 11 patients, nine had a durable partial response and two achieved stable disease
  • Results were achieved from third- through sixth-line therapy

*Hidalgo, M. et al. Mol Cancer Ther, 2011. 10(8): p. 1311-6

Recent Scientific Publications and Case Studies >

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology